Pharsight

Array Biopharma Inc patents expiration

1. Braftovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8946250 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Jul, 2029

(5 years from now)

US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(6 years from now)

USRE49556 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Feb, 2030

(6 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(7 years from now)

US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Nov, 2032

(9 years from now)

US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
Aug, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 2022-06-27

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, a...

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

2. Mektovi patents expiration

MEKTOVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(6 months ago)

US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2024

(5 months from now)

US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8513293 ARRAY BIOPHARMA INC Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
Mar, 2023

(6 months ago)

US8193229 ARRAY BIOPHARMA INC Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(6 months ago)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(7 years from now)

US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: 2022-06-27

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with encorafenib for the treatment of melanoma; Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indi...

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic